Akebia Company Profile
What is the competitive landscape for AKEBIA
AKEBIA has one approved drug.
There are fourteen US patents protecting AKEBIA drugs.
Drugs and US Patents for Akebia
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akebia | VAFSEO | vadadustat | TABLET;ORAL | 215192-003 | Mar 27, 2024 | DISCN | Yes | No | 9,701,636 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Akebia | VAFSEO | vadadustat | TABLET;ORAL | 215192-001 | Mar 27, 2024 | RX | Yes | No | 11,324,734 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Akebia | VAFSEO | vadadustat | TABLET;ORAL | 215192-003 | Mar 27, 2024 | DISCN | Yes | No | 9,987,262 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Akebia | VAFSEO | vadadustat | TABLET;ORAL | 215192-001 | Mar 27, 2024 | RX | Yes | No | 9,701,636 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Akebia | VAFSEO | vadadustat | TABLET;ORAL | 215192-002 | Mar 27, 2024 | RX | Yes | No | 7,811,595 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Akebia | VAFSEO | vadadustat | TABLET;ORAL | 215192-002 | Mar 27, 2024 | RX | Yes | No | 11,857,543 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Akebia | VAFSEO | vadadustat | TABLET;ORAL | 215192-001 | Mar 27, 2024 | RX | Yes | No | 11,844,756 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Akebia Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2705587 | ⤷ Start Trial |
| China | 105451739 | ⤷ Start Trial |
| New Zealand | 759132 | ⤷ Start Trial |
| Russian Federation | 2021125455 | ⤷ Start Trial |
| South Korea | 102495018 | ⤷ Start Trial |
| Ecuador | SP17073209 | ⤷ Start Trial |
| South Korea | 20160083118 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Akebia Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3007695 | C202430024 | Spain | ⤷ Start Trial | PRODUCT NAME: VADADUSTAT; NATIONAL AUTHORISATION NUMBER: EU/1/23/1725; DATE OF AUTHORISATION: 20230424; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1725; DATE OF FIRST AUTHORISATION IN EEA: 20230424 |
| 3007695 | CR 2024 00026 | Denmark | ⤷ Start Trial | PRODUCT NAME: VADADUSTAT; REG. NO/DATE: EU/1/23/1725 20230425 |
| 3007695 | PA2024521 | Lithuania | ⤷ Start Trial | PRODUCT NAME: VADADUSTATAS; REGISTRATION NO/DATE: EU/1/23/1725 20230424 |
| 3007695 | 202440023 | Slovenia | ⤷ Start Trial | PRODUCT NAME: VADADUSTAT; NATIONAL AUTHORISATION NUMBER: EU/1/23/1725; DATE OF NATIONAL AUTHORISATION: 20230424; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 3007695 | 122024000039 | Germany | ⤷ Start Trial | PRODUCT NAME: VADADUSTAT (VAFSEO); REGISTRATION NO/DATE: EU/1/23/1725 20230424 |
| 3007695 | CA 2024 00026 | Denmark | ⤷ Start Trial | PRODUCT NAME: VADADUSTAT; REG. NO/DATE: EU/1/23/1725 20230425 |
| 3007695 | 24/2024 | Austria | ⤷ Start Trial | PRODUCT NAME: VADADUSTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1725 (MITTEILUNG) 20230425 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.

